Navigation Links
China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
Date:9/10/2008

HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully developed 26 new drugs that are currently in clinical trials.

Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned subsidiary of China Sky One Medical, recently completed research and development for the 26 new drugs, which have been submitted to the State Food and Drug Administration (SFDA) in the PRC for approval.

-- Four drugs, including Cleaning suppositories, Tinidazole

suppositories, Policresulen vaginal suppositories, and Aciclover gel

are for the treatment of vaginits;

-- Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium

Chloride and Compound Chlorhexidine, are gargles for the treatment

of toothache;

-- Three drugs, including Diclofenac Sodium Suppositories, Paediatric

Ibuprofen suppositories and Musky cream, are for pain relief;

-- Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture

and Nitrofurantoin suppositories, are anti-infectives;

-- Two drugs, including Collunarium and Compound Naphazoline Spray, are

for the treatment of rhinopathy;

-- Two drugs, including Sulfasalazine suppositories and Sodium ferulate

injection are for the treatment of cardiovascular disease;

-- Methionine Vitamin B1 injection is for improving liver function;

-- Doxofylline injection is for the treatment of asthma;

-- Pantoprazole sodium injection is for the treatment of canker sores;

-- Calcium Folinate injection is intended as an antidote for folic acid

deficiency;

-- Hydrastis suppositories are for the treatment of colds; and

-- The final four drugs, including hemorrhoids gel, hemorrhoids liquids,

chilblain cream and expectorant, are all externally used.

"We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over- the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
6. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ® Technologies, Inc. announces that the Journal ... of Vibration on Molar Distalization," a study that focused ... Bowman , this prospective, peer-reviewed clinical study concluded that ... speeds up molar distalization rates in the apex ... to move the upper molars into a normal, Class ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company ... clinical study for its dental gel that shows significant reduction in plaque levels and ... triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine and ...
(Date:1/17/2017)... ... , ... Many people make New Year’s resolutions or renew their commitment to better health with ... for people who want to kick off 2017 with better smiles. Dr. Mondavi is offering ... special offers include: , , A new patient package for just ...
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... 2017 , ... Houston dentist, Dr. Behzad Nazari, announces that ... and financing for orthodontics for a limited time. Complimentary for a limited time, ... orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine Dental also ...
Breaking Medicine News(10 mins):